
1.1K
Downloads
58
Episodes
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Episodes
6 hours ago
6 hours ago
9 min
E70 | 10 min | Latest | Publication Link
- Podcast based on: Gennari, P.; Busse, M.; Ignatov, A. Metastasis-Directed Therapy Versus Systemic Therapy in Oligometastatic Endometrial Carcinoma Recurrence: A Population-Based Registry Analysis. Cancers 2026, 18, 3382. https://doi.org/10.3390/cancers18203382
Type: Article | Publication date: 19 October 2026 - Summary: Endometrial cancer sometimes returns as a small number of distant metastases. Doctors can then treat these metastases directly, for example with surgery or focused radiotherapy, or treat the whole body with drugs such as chemotherapy. It is unknown which approach helps patients live longer. We analyzed data from a regional cancer registry in Germany covering 153 women whose cancer had returned in one or two distant sites. After statistical adjustment for differences between the groups, women treated directly at the metastases and women treated with drugs survived for a similar length of time. However, women with high-grade tumors appeared to live longer after direct treatment of the metastases. This finding is preliminary and needs to be confirmed in prospective studies before it can change clinical practice.
- Keywords: endometrial carcinoma; oligometastatic recurrence; metastasis-directed therapy; stereotactic body radiotherapy; inverse probability of treatment weighting; propensity score; population-based registry; high-grade endometrial cancer
License and disclaimer:
Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.
6 hours ago
9 min

No comments yet. Be the first to say something!